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Recent progress in chimeric antigen receptor-modified T-cell (CAR-T cell) technology in cancer therapy is extremely promis-
ing, especially in the treatment of patients with B-cell acute lymphoblastic leukemia. In contrast, due to the hostile immuno-
suppressive microenvironment of a solid tumor, CAR T-cell accessibility and survival continue to pose a considerable chal-
lenge, which leads to their limited therapeutic efficacy. In this study, we constructed two anti-MUC1 CAR-T cell lines. One set 
of CAR-T cells contained SM3 single chain variable fragment (scFv) sequence specifically targeting the MUC1 antigen and 
co-expressing interleukin (IL) 12 (named SM3-CAR). The other CAR-T cell line carried the SM3 scFv sequence modified to 
improve its binding to MUC1 antigen (named pSM3-CAR) but did not co-express IL-12. When those two types of CAR-T 
cells were injected intratumorally into two independent metastatic lesions of the same MUC1+ seminal vesicle cancer patient as 
part of an interventional treatment strategy, the initial results indicated no side-effects of the MUC1 targeting CAR-T cell ap-
proach, and patient serum cytokines responses were positive. Further evaluation showed that pSM3-CAR effectively caused 
tumor necrosis, providing new options for improved CAR-T therapy in solid tumors. 
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INTRODUCTION 
T-cell based immunotherapy is becoming a hotspot of the 
cancer therapeutics area. Specifically, using gene transfer 
technologies, patient T-cells can be genetically modified to 
stably express single-chain variable fragments (scFv) or 
ligands capable of binding antigens or receptors, respec-
tively, to confer novel major histocompatibility complex 
(MHC)—independent antigen specificities on tumor cells. 
These structures are called chimeric antigen receptors 
(CARs) and contain three basic elements—the extracellular 
antigen binding domain, transmembrane domain, and cyto-
plasmic signaling domain. First-generation CARs featured a 
single signaling domain most commonly derived from the 
CD3 component of TCR (T cell receptor)/CD3 complex. 
Second- or third-generation CARs were designed by in-
cluding additional signaling domains, such as CD28 and/or 
4-1BB, that potentiate T-cell effector functions and activate 
co-stimulatory pathways, resulting in upregulation of genes 
encoding anti-apoptotic proteins and increased cytokine 
secretion. With this strategy, a complete remission among 
30 children and adults who received CD19-targeting 
CAR-T cell therapy for relapsed or refractory acute lym-
phoblastic leukemia (ALL) was achieved with 90% success 
rates (Porter et al., 2011, Davila and Brentjens, 2013; Grupp 
et al., 2013, Jensen and Riddell, 2014; Maude et al., 2014, 
2015; Pegram et al., 2014; Turtle, 2014; Condomines et al., 
2015; Jonnalagadda et al., 2015).  
In solid tumor therapy, CAR-T cells showed little thera-
peutic efficacy for the following reasons: (i) off-target tox-
icity due to the expression of target antigens in normal tis-
sue; (ii) heterogeneity of tumor lesions with the tar-
get-negative tumor cells ultimately becoming the dominant 
population, and most importantly; (iii) release of immune 
repressive cytokines, such as transforming growth factor 
(TGF)  and interleukin (IL) 10, by tumor cells, and pres-
ence of suppressive cells, such as regulatory T-cells (tregs) 
and tumor-associated macrophages (TAMs), etc., creating 
an immunosuppressive microenvironment encasing the tu-
mor cells and significantly inhibiting CAR-T cell homing 
abilities (Kakarla and Gottschalk, 2014; Lamers et al., 2014; 
Abken, 2015; Hillerdal and Essand, 2015). Accordingly, 
some research groups have engineered IL-12 co-expressed 
CAR-T-cells at the tumor foci to suppress the unfavorable 
tumor microenvironment. IL-12 is a heterodimeric inflam-
matory cytokine produced by activated antigen-presenting 
cells (APCs), neutrophils, and macrophages, that also in-
duces Th1 CD4+ T-cell response. IL-12 can serve as signal 
3, in concert with TCR activation (signal 1) and CD28 
costimulation (signal 2) of CD8+ T-cells, resulting in opti-
mized clonal expansion and effector function. IL-12 induces 
proliferation and cytotoxic activity of natural killer (NK) 
cells and generates anti-tumor activity through the effector 
cell-produced cytokines, including interferon-gamma 
(INF-), which in turn upregulate tumor cell Fas (CD95) 
and FasL. More significantly, IL-12 has been shown to 
modulate the hostile tumor microenvironment through mul-
tiple mechanisms, including reactivation of anergic tu-
mor-infiltrated lymphocytes (TILs), inhibition of 
Treg-mediated suppression of the effector T-cells, recruit-
ment of NK cells to the tumor site, and inhibition of TAM 
IL-10 and transforming growth factor- (TGF-) secretion 
(Chinnasamy et al., 2012; Chmielewski et al., 2014; 
Chmielewski and Abken, 2015; Pegram et al., 2015). 
Appropriate tumor targets need to be identified to mini-
mize the off-target effect of CAR-T cells. Mucin 1 (MUC1) 
is becoming an interesting target in cancer immunotherapy, 
for three reasons. First, aberrant expression of MUC1 has 
been reported in most solid tumors and many hematologic 
malignancies (Kruger et al., 2000; Jonckheere and Van 
Seuningen, 2010). Second, whereas MUC1 is normally con-
fined to the luminal epithelium, this polarity of expression is 
lost upon malignant transformation. Third, glycosylation of 
MUC1 is largely deregulated in cancer. Owing to an altered 
glycosyltransferase expression, tumor-associated MUC1 is 
decorated by a preponderance of shorter glycans, including 
Thomsen-nouveau (Tn), sialyl Tn (STn), Thomsen- 
Friedenreich (T), and sialyl-T (ST). Under-glycosylation of 
MUC1 unmasks cryptic epitopes within the extracellular 
domain containing a variable number of tandem repeats 
(VNTR), enabling tumor-selective binding by several anti-
bodies (Abs) (Acres and Limacher, 2005; Yang et al., 2007; 
Tang and Apostolopoulos, 2008; Tang et al., 2008; Beatson 
et al., 2010; Kimura and Finn, 2013; Madsen et al., 2013; 
Acres et al., 2015). Some research groups recently reported 
their efforts in developing MUC1-CAR-T cells, in which 
SM3 scFv, a renowned antibody with tumor-associated 
MUC1 selectivity, was used for constructing CD28-CD3 
CAR. However, the resultant SM3-CD28-CD3 CAR 
proved extremely poor in retargeting human T-cells toward 
a variety of MUC1-expressing tumor cells. These disap-
pointing results illustrated the existence of two types of ste-
ric inhibition, one imposed by the large size of immobilized 
MUC1 and the other by its heterogeneous glycosylation. 
The precise binding properties of SM3 to tumor-associated 
MUC1 were then analyzed and found to be suboptimal. In 
particular, SM3 did not bind to MUC1-ST, which is widely 
expressed by many tumor cells. Another anti-MUC1 scFv, 
of HMFG2, was identified, differing from SM3 by five 
amino acids and exhibiting a 7.4-fold-higher affinity for 
unglycosylated MUC1, which was sufficient to enable 
T-cells grafted with this CAR to proliferate robustly when 
plated on anchored glycan-free MUC1. Accordingly, 
HMFG2-CD28-OX40-CD3z CAR was tested in a preclini-
cal model, which resulted in a significant delay of tumor 
growth (Wilkie et al., 2008; Maher and Wilkie, 2009; 
Gheybi et al., 2014).  
No clinical trial has been reported to date for 
MUC1-targeting CAR-T therapy. Here, we present a case 
report from a first-in-human study of MUC1-specific 
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CAR-T cells in a patient with MUC1-expressing seminal 
vesicle cancer. In order to reduce the off-target effect of 
CAR-T cells and overcome the immune suppressive micro-
environment of tumor foci, we constructed two MUC1- 
CAR-T platforms. One platform comprised SM3-CD28- 
CD137-IL12 CAR (SM3-CAR), and the other pSM3-CD28- 
CD137 CAR (pSM3-CAR) with a mutated SM3 scFv se-
quence to improve SM3 binding to MUC1 ST glycans. In 
addition, we incorporated a novel strategy of CAR-T cell 
delivery, intratumoral injection. Consequently, we obtained 
clinical evidence of tumor responses with pSM3-CAR. Our 
data thus support the feasibility of pSM3-CAR-T cell ap-
proach, in combination with an interventional treatment, as 
a novel strategy for the treatment of patients with MUC1+ 
solid malignancies, and suggest therapeutic benefits of 
pSM3-CAR-T cells.  
RESULTS 
Preclinical analysis  
One metastatic seminal vesicle cancer patient was enrolled 
in the trial. Before we recruited him into the program, biop-
sies from pleural and intraperitoneal metastases (cell smears 
and tissue sections) from this patient was stained for MUC1 
expression. Notably, strong MUC1 expression was observed 
(Figure 1A and B), more pronounced in the biopsy material 
than in MUC1-positive MCF7 control cells. To further ver-
ify MUC1 positivity, primary tumor cells were also as-
sessed by western-blot and flow cytometry assays. Consist-
ently, the tumor cells were also highly MUC1 positive 
(Figure 1C and D). Immunohistochemistry confirmed 
MUC1 expression in patient tumor biopsies (data not 
shown). We therefore concluded that, for this patient, 
MUC1 can be used as a CAR-T cell therapy antigen. 
Anti-MUC1-CAR design 
In general, the scFv fragment contributes to new antigen 
specificity of a CAR-T cell, whereas intracellular CAR sig-
naling domains are responsible for the functional outcome 
of CAR-mediated T-cell activation. MUC1 is commonly 
over-expressed in tumors and it has been predicted to be a 
potential target of immune therapy in about 80% of all can-
cer cases (Acres and Limacher, 2005). It is, however, also 
expressed in normal tissues, albeit as a different glycoform 
(Wilkie et al., 2008). Accordingly, the scFv sequence for 
CAR construction had to be very carefully selected. 
MUC1-specific monoclonal antibodies (MAbs) distinguish 
healthy MUC1 from cancer-associated MUC1 (Kimura and 
Finn, 2013; Madsen et al., 2013). This is supported by evi-
dence from the Joyce Taylor-Papadimitriou laboratory, who 
showed in a series of excellent experiments that antibodies 
targeting the human milk fat protein mucin-1 chemically 
stripped of its carbohydrate side chains specifically reacted 
with the cancer-associated MUC1 glycoprotein (Gendler et 
al., 1991; Taylor-Papadimitriou et al., 1993). This suggested 
that cancer associated MUC1 is non- or at least un-
der-glycosylated in comparison with the normal MUC1 
glycoprotein. Among the characterized MUC1 antibodies, 
clone SM3 is renowned for its selectivity against tu-
mor-associated MUC1 (Granowska et al., 1990; Burchell 
and Taylor-Papadimitriou, 1993; Granowska et al., 1993; 
Wilkie et al., 2008), we therefore first constructed SM3 
scFv-based CAR with IL-12 co-expression (SM3-CAR). 
Because it has been reported that 4-1BB domain may en-
hance CAR-T cell persistence, our final version of 
SM3-CAR contained SM3 scFv fused to sequences derived 
from CD28, 4-1BB, and CD3, followed by an internal ri-




Figure 1  MUC1 expression in patient tumor biopsies. A, Immunostaining of patient primary tumor cells for surface MUC1 expression. MUC1+ MCF7 
cells were used as positive control. B, Immunostaining of patient primary tumor cells for intracellular MUC1 expression. MUC1+ MCF7 cells were used as 
positive control. C, Flow cytometry assay was used to detect MUC1 expression on patient primary tumor cells. D, Western-blot was performed to detect 
MUC1 expression in patient primary tumor cells and MCF7 cells respectively. 
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Figure 2  Schematic illustration of the MUC1 specific CAR. A, SM3-CAR consists of a signal peptide (SP), SM3 scFv as an extracellular domain, an Fc 
domain, a CD28 transmembrane domain, and an intracellular signal transduction domain CD3-z, followed by IRES driven IL-12 molecules. B, pSM3-CAR 
includes a mutated SM3 scFv in which six amino acids were changed to improve its binding ability to tumor associated MUC1. In addition, pSM3-CAR 
contains a IgD hinge fragment to increase its flexibility. In contrast to SM3-CAR, pSM3-CAR has no IRES driven IL-12 molecules. C, Expression of IL-12 
in condition medium of SM3-CAR-T cells co-cultured with/without MUC1+ T47D cells was examined by the enzyme-linked immunosorbent assay (ELISA).  
SM3 scfv mutation improves tumor-associated MUC1 
binding capacity 
Since SM3 scFv-derived CAR was extremely poor in retar-
geting human T-cells against a variety of MUC1-expressing 
tumor cells, we were concerned that our new SM3-CAR 
may lead to disappointing clinical outcomes regardless of 
the inclusion of IL-12. Recent studies by the Maher group 
suggested that scFv sequence cloned from HMFG2 hy-
bridoma formed against MUC1 exhibited superior binding 
to tumor-associated MUC1, especially when the CAR com-
prised an IgD hinge fragment that provided greater flexibil-
ity and access to the epitope, thereby overcoming steric in-
hibition (Wilkie et al., 2008). Based on these findings, we 
mutated six amino acids in the SM3 scFv sequence. The 
mutated form of SM3 scFv (pSM3 scFv) was fused to the 
Fc domain and IgD hinge fragment, and used to construct 
CD28-4-1BB-CD3 CAR (pSM3-CAR). This construct did 
not contain IL-12 (Figure 2B). 
Characterization of MUC1-CAR-T cells 
Lentiviral SM3-CAR and pSM3 particles were prepared as 
described in Materials and methods. Thirty MOI (multiplic-
ity of infection) suspensions of SM3-CAR or pSM3-CAR 
lentiviruses, 1108 mL1 titers, were used to separately 
transduce the patient’s T-cells. Flow cytometry assays indi-
cated similar transduction efficiencies for the two CARs, 
and 21% and 18% of SM3-CAR-T- and pSM3-CAR-T- 
positive cells, respectively, were observed (data not shown).  
A series of in vitro immunology assays was used to fur-
ther evaluate the constructs. Cytotoxicity assays were used 
to evaluate SM3-CAR-T cells against T47D cells, an en-
dogenous MUC1-expressing tumor cell line (data not 
shown). Untransduced T cells and CD19-CAR lentiviral 
vector transduced T cells were served as negative control 
(Figure 3A and B), which showed basic cytolytic activity 
toward T47D cells (15% and 21% respectively) with a E:T 
ratio (effector:target) of 30:1. In contrast, SM3-CAR-T 
cells and pSM3-CAR-T cells had greater cytolytic activity 
toward T47D cells. As shown in Figure 3C and D, when 
E:T ratio was 30:1, SM3-CAR-T and pSM3-CAR-T cells 
killed T47D cells up to 44% and 51% respectively.  
Clinical antitumor response of MUC1-CAR-T cells 
After SM3-CAR-T cells and pSM3-CAR-T cells were in-
jected into two separate tumor lesions respectively and sim-
ultaneously as described in Materials and methods, we 
monitored the patient’s responses as frequently as possible 
since we employed an interventional treatment strategy in 
this study. The patient began to suffer from mild headache, 
muscle pain, nasal congestion, and mild abdominal bloating 
discomfort, but with normal breath, blood pressure, pulse, 
and oxygen saturation, one day after the intratumoral injec-
tion. The patient’s basal body temperature was 36.1°C be-
fore the initiation of CAR-T therapy, and increased to 
38.2°C on third day post-injection, implying a positive re-
sponse to the therapy (Figure 4A). From the sixth to twelfth  
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Figure 3  (color online) Cytotoxicity assays of MUC1 targeted CAR-T 
cells against MUC1 positive cells of T47D in vitro. A, Non-transduced T 
cells. B, CD19-CAR lentiviral vector transduced T cells. C, SM3-CAR-T 
cells (E:T=30:1). D, pSM3-CAR-T cells (E:T=30:1); T47D cells were 
incubated with CAR T cells or control T for 24 hrs. Lysis of the tumor cells 
was quantified using 7-AAD assay. 
day post the intratumoral injection, all discomforts disap-
peared and the body temperature returned to normal. How-
ever, started from 13th day of post-intratumoral injection, 
patient experienced 1–3 times of loose stools daily for two 
days with a paste shape, although the stool color was nor-
mal. And at the 15th day of post-intratumoral injection, there 
were blood found three times in the stools after the patient 
drinking cleaning fluid intestinal phosphate.  
The patient’s blood analysis indicated some abnormali-
ties, including increased eosinophil ratio and counts, and 
elevated glucose levels (Table 1), suggesting an inflamma-
tory response, or an acute response. In comparison with the 
basal uric acid levels, which were within normal range (Ta-
ble 1), the patient’s uric acid levels post injection increased, 
implying a possible minor kidney dysfunction. 
The patient was examined to evaluate the impact of  
CAR-T cell treatment on immune activation. This was ac-
complished by soluble immune-factor profiling of serum 
samples collected at defined time points. IL-6 and tumor 
necrosis factor alpha (TNF-) were determined, as well as 
CRP (C reaction protein), which has been reported to be 
associated with IL-6 expression (Barrett et al., 2014). A 
transient cytokine release syndrome , with a 10 folds in-
crease of IL-6 and ca. 60% increase of TNF- levels, was 
detected after intratumoral injection. The cytokines re-
mained elevated for 21 d, until biopsies of the treated tumor 
were surgically analyzed. Larger increases of CRP levels 
were observed on the second and third day post-  intra-
tumoral injection, and remained elevated (Figure 4B). Alt-
hough it is not clear from the cytokine data whether this 
effect was due to SM3-CAR-T cells or pSM3-CAR-T cells, 
at least some CAR-T cells triggered the patient’s immune 
response.      
To fully evaluate the therapeutic efficacy of CAR-T cells 
and determine if SM3-CAR-T or pSM3-CAR-T cells bene-
fit the patient better, ultrasonographic images were taken at 
the 21st day of post-intratumoral injection, followed by a 
surgical resection of the tumors. Unfortunately, SM3-CAR- 
T tumor showed little necrosis (image data not shown), in-
dicating that SM3-CAR-T cells failed to recognize tumor 
cells even IL-12 was co-expressed. In contrast, pSM3-CAR- 
T-treated tumor had two necrotic areas, including an old 
necrotic area, which might have been caused by a previous 
hypoxia, and a new necrotic area, which perfectly matched 
the sites of pSM3-CAR-T cell injections (Figure 5). This 
indicated that mutating SM3 scFv may indeed have im-
proved binding to tumor-associated MUC1 and, conse-
quently, tumor cell killing.   
Furthermore, tumor biopsies were analyzed by immuno-
histochemistry assay. As shown in Table 2, SM3-CAR-T 
tumor and pSM3-CAR-T tumor both have infiltrated CD4+ 
T cells, as well as CD3+/CD8+ T cells, suggesting the per-
sistence of intratumorally injected T cells. Interestingly, one 
major difference between SM3-CAR-T tumor and pSM3- 
CAR-T tumor was positive TIA-1 expression in SM3-CAR- 
T tumor but not in pSM3-CAR-T tumor, which may be 
contributed by co-expression of IL-12 molecule in SM3- 
CAR-T tumor. Impressively, significant necrosis event was 
observed in pSM3-CAR-T tumor as shown in circled and 
arrowed upper left panel of Figure 6A. We also examined  
Table 1  Representative blood test results 
Item Before treatment Post treatment day 1 Post treatment day 5 Post treatment day 20 Post treatment day 26 Normal range
Eosinophil ratio 14.3% 6% 14% 11.7% 12.9% 0.4%–0.8% 
Eosinophil counts 0.70 0.48 0.88 0.73 0.88 0.02–0.52 
PO4 1.26 1.17 1.52 1.18 0.75 0.81–1.45 
Urea 5.5 4.67 6.03 5.7 2.82 3.30–8.22 
Uric 133 281 266 266 137 240–490 
LDH 162 145 290 148 129  11–220 
Glucose 4.48 4.76 4.49 7.45 6.87 3.9–5.9 
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Figure 4  (color online) Patient response to CAR-T treatment. A, Patient body temperature measurement during the CAR-T cells treatment. B, Patient 
serum cytokines detection during the CAR-T cells treatment. The unit of vertical ordinate for IL-6 and TNF is pg mL1, for CRP is mg L1. 
Table 2  Histopathological analysis of resected tumors 
Item SM3-CAR-T-treated tumor pSM3-CAR-T-treated tumor 
Morphology Aggregated tumor cells nested in fibrous connective tis-
sue, with adenocarcinoma invasion/metastasis 
Aggregated tumor cells nested in fibrous connective tissue, 
with adenocarcinoma invasion/metastasis 
Tumor necrosis Little necrosis Significant multiple necrotic foci 
Infiltration event Lymphocytic mononuclear cell infiltration Lymphocytic mononuclear cell infiltration 
Hemorrhage Some  Some 
Fibrosis Positive  Positive  
Major infiltrating immune 
cells 
CD3+/CD8+ T-cells, CD68+ mononuclear cells, and Fc+ 
CAR-T cells 
CD3+/CD8+ T-cells, CD68+ mononuclear cells, and Fc+ 
CAR-T cells 
Minor infiltrating immune 
cells 
CD4+ T-cells, CD56+/Granzyme B+ cells, CD20+ cells CD4+ T cells, CD56+/Granzyme B+ cells, CD20+ cells 
TIA positive cells Yes No 
B-cell phenotype CD20+, CD19 CD20+, CD19 
Tumor cell phenotype MUC1+ MUC1+ 
 
the MUC1 expression in the tissue sections. Majority of 
pSM3-CAR-T tumor cells lose MUC1 expression, indicat-
ing an event of apoptotic tumor cells. A few pSM3-CAR-T 
tumor cells showed MUC1 positive staining but without 
nuclei staining (Figure 6C), suggesting that those are dying 
tumor cells. CD4+ and CD8+ T cells were observed in both 
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Figure 5  Ultrasonographic images of the metastatic lesions of seminal vesicle carcinoma. A, Grayscale ultrasound illustrated a well defined heterogeneous 
tumor lesion measuring 3.2 cm×2 cm at the upper abdomen. The echolucent area (arrow head) indicated necrosis inside the tumor before treatment. The 
hypoechoic area (arrow) was selected for the injection of CAR-T cells. B, A 23G needle was used for the injection. With the guidance of real time ultrasound, 
the needle was precisely inserted in the targeted area. The arrow head represented the insertion point of needle tip. The arrow indicated a convex echogenici-
ty caused by injectd CAR-T cells. C, 21 d after the injection of CAR-T cells, grayscale ultrasound showed that the injected area became anechoic (arrow), 
suggesting necrosis of the tumor cells. 
 
Figure 6  Characterization of CAR-T cell treated biopsies. pSM3-CAR tumor showed prominent necrosis of the tumor cells (A, B, arrowed), which were 
MUC-1+ (as could be appreciated from the immuno-positivity of viable tumor cells around necrotic debris, C), together with more prominent lymphocytic 
infiltrates, mostly of CD4+ (D) or CD8+ (E) T cells, but not TIA-1+ cell (F). Necrosis was not observed in SM3-CAR tumor (H, I), the cells of which were 
also MUC-1+ (J), but CD4+ (K) and CD8+ (L) T cells were also present inside or around tumor cell nests, although to a lesser extent in comparison to 
pSM3-CAR tumor (D, E). Scattered TIA-1+ cells were also observed in SM3-CAR tumor (M). Existence of CAR-T cells were demonstrated in frozen biop-
sies (G, N).  
biopsies (Figure 6D, E, K and L), demonstrating persistence 
of CAR-T cells, which was further supported by anti-Fc 
staining on frozen tissue sections (Figure 6G and N). 
DISCUSSION 
CAR-T cell immunotherapy has shown great antitumor po-
tential in patients with hematologic malignancies in many 
trials, especially in ALL (Maude et al., 2014). However, 
antitumor effects of CAR-T cell approaches in solid malig-
nancies were disappointing. This was, in part, due to 
off-tumor on-target toxicities, as has been observed in 
CAR-based clinical studies that have targeted carbonic an-
hydrase IX (CAIX), which is overexpressed in renal cell 
carcinoma but also expressed at low levels in normal tis-
sues, including the liver (Lamers et al., 2013). The first le-
thal case in CAR-T therapy involved a patient with colon 
cancer that has metastasized to the lungs and the liver and 
was refractory to multiple standard treatments. The patient 
with ERBB2 (receptor tyrosine-protein kinase erbB-2)- 
overexpressing tumors underwent a third-generation CAR 
therapy based on the widely used humanized mAb 
trastuzumab (herceptin). The patient received 1010 CAR-T 
cells intravenously, but experienced respiratory distress 
within 15 min of the infusion, developed a dramatic pul-
monary infiltrate (detected in chest X-ray image after 40 
min of completion of the infusion), and died five days after 
treatment. It has been postulated that death resulted from the 
transfer of highly active anti-ErbB2- directed T-cells. Upon 
first-pass clearance in the lung, these cells recognized 
ErbB2 expressed by normal lung cells, and released in-
flammatory cytokines (including TNF- and IFN-) that 
caused pulmonary toxicity and edema. This was followed 
by a cascading cytokine storm and resulted in multi-organ 
failure, similar to the multiple organ dysfunction syndrome 
caused by a variety of acute physiological insults (e.g., 
trauma or severe infections) (Morgan et al., 2010). 
Another obstacle in CAR-T therapy of solid malignances 
is the immunosuppressive microenvironment created by 
tumor cells, which impairs the CAR-T cell homing ability. 
T-cell homing is an outcome of an as-yet incompletely un-
derstood interplay of a wide range of molecular interactions, 
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and great efforts are invested to delineate the molecular 
mechanisms that underpin this phenomenon. The chemo-
kine system may play a major part in driving T-cell migra-
tion and the expression of specific chemokine receptors can 
aid the precise trafficking of T-cells to tumors. Examples 
include co-expression of CXCR2 to encourage engineered 
T-cell migration towards melanoma (Lutschg et al., 2011), 
and CCR2b expression for T-cell migration towards neuro-
blastoma (Craddock et al., 2010). In addition, with respect 
to the immunosuppressive nature of the tumor milieu, 
TGF-, a candidate suppressive cytokine produced by tu-
mor cells, represses the proliferation of both CD4+ and 
CD8+ CAR-T cell subsets but does not repress IFN- secre-
tion of CAR-T cells or specific CAR-T cell cytolytic activi-
ty. CD28 co-stimulation overcomes the TGF--mediated 
repression of T-cell proliferation (Koehler et al., 2007), re-
flected by a more pronounced killing of tumor cells. Fur-
thermore, in a CD28-CD3 CAR, deletion of the lympho-
cyte-specific protein kinase (LCK) binding site in the CD28 
endodomain could improve anti-tumor activity of the 
CAR-T cells even though Treg cells are present in the tumor 
lesion (Kofler et al., 2011). Thus, CARs with the modified 
CD28 endodomain are expected to expedite the implemen-
tation of CAR-T cell therapy in patients whose tumors are 
heavily infiltrated by Tregs. CAR-T cell-mediated recruit-
ment of other components of the immune system and their 
involvement in an antitumor response represent another key 
aspect of improving the therapeutic efficacy of CAR-T 
cells. Experiments with constructs comprising the CAR 
expression vector and a responsive cytokine gene expres-
sion-driving promoter have demonstrated that CAR-T cells 
can produce high levels of cytokines upon antigen binding. 
Indeed, studies have shown that therapy with CAR-T cells  
engineered to release IL-12 result in an enhanced recruit-
ment of innate immune cells and reinforcement of their 
functions (Pegram et al., 2012; Chmielewski and Abken, 
2015). Notably, Chmielewski et al. showed that IL-12 se-
cretion induced upon CAR engagement resulted in the de-
struction of antigen-negative cancer cells that would nor-
mally escape the T-cell therapy (Pegram et al., 2012; 
Chmielewski and Abken, 2015). The above-mentioned re-
ports indicate that Th1-driving cytokines, such as IL-12, can 
muster a macrophage response towards tumor cells that 
have ceased tumor antigen expression, in otherwise inac-
cessible tumor lesions, in a manner associated with a local-
ized proinflammatory response and reduced systemic tox-
icity. It is important to identify whether other cytokines or 
immune-potentiating molecules can strengthen and fi-
ne-tune the overall patient immune response towards solid 
tumors, thereby amplifying the antitumor effect driven by 
the CAR-T cells and to establish an immunological memory 
to challenge recurrence of the tumor.   
Given the above-mentioned reasons, it is critical to con-
sider potential off-target toxicities and strategies that miti-
gate these toxicities in the early clinical developments of 
CAR-T cell solid malignancies approaches. Here, we have 
shown the feasibility of employing CAR-T cells using a 
mutated anti-MUC1 scFv (pSM3) construct based on SM3 
sequence. We have explored the safety and bioactivity of 
MUC1-redirected CAR-T cells in a patient with advanced 
seminal vesicle carcinoma. MUC1 is a well-established tu-
mor associated antigen (TAA), which is abnormally ex-
pressed in a variety of cancer cells, predominantly epithelial 
tumors (Jonckheere and Van Seuningen, 2010). MUC1 is 
commonly over-expressed in tumor-associated form that has 
been predicted to be a potential target of immune therapy 
for about 80% of all cancer cases (Kimura and Finn, 2013). 
It is also expressed in normal tissues (Peat et al., 1992), al-
beit as a different glycoform. It is noteworthy that the first 
detailed report of T-cell response to MUC1 in humans was 
very unusual in that the T-cells were not specific to MUC1 
peptide sequences within the target surface MHC I (Barnd 
et al., 1989). Rather, they were MHC I-unrestricted and 
were specifically blocked by SM3 antibody raised against 
MUC1 protein core. Therefore, we chose SM3 scFv se-
quence as our initial candidate for constructing CAR-T 
cells. However, a previous report indicated that SM3 bind-
ing to tumor-associated glycoforms of MUC1 was inade-
quate (Wilkie et al., 2008). Therefore, Wilkie et al. devel-
oped a modified scFv construct that improved the retarget-
ing capacity of tumor-associated MUC1-specific CAR 
(Wilkie et al., 2008). We mutated six amino acids in the 
SM3 scFv sequence to mimic HMFG2, and with further 
optimization, we obtained an artificial scFv sequence of 
pSM3. Our findings show that the safety of pSM3-CAR-T 
cells was acceptable for intratumoral delivery, by injection, 
and mediated antitumor activity in vivo, including the in-
duction of epitope spreading. We detected evidence of anti-
tumor activity despite no pretreatment lymphodepletion. 
Meanwhile, although SM3-CAR-T cells showed cytotoxi-
city toward T47D cells in vitro, they failed to kill the pa-
tient’s tumor cells in vivo even though IL-12 was artificially 
co-expressed with SM3-CAR. This suggested that the scFv 
element plays a vital role in CAR-T cell therapy.   
We designed two types of CAR-T constructs to evaluate 
the safety and efficacy of CAR-T cells. One, SM3-CAR, 
was predicted to bind tumor-associated MUC1 poorly, but 
the constructed cell line co-expressed IL-12. We hypothe-
sized that IL-12 would play a major role against tumor cells 
if the engineered CAR-T cells would not be able to fully 
recognize their tumor target. The other CAR, pSM3-CAR, 
comprised a mutated SM3 scFv sequence to improve its 
binding to tumor-associated MUC1 in the absence of engi-
neered IL-12 co-expression. This experimental approach 
was designed to demonstrate the role of tumor antigen tar-
geting in a cancer patient treatment. We observed little 
therapeutic benefits when using SM3-CAR-T cells, but an 
obvious anti-tumor activity exerted by pSM3-CAR-T cells, 
suggesting that a careful choice of the target antigen, and 
the appreciation of its accessibility and expression levels, 
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must be considered in future proposals of CAR-T cell clini-
cal trials.    
However, target antigen selection and CAR-T cell intra-
tumoral injection constitute only the first step toward treat-
ment and cure of solid tumors. Considerable challenges still 
remain for CAR-T cell therapy. For example, given the long 
timeline of tumorigenesis, most solid tumors are invariably 
less oxygenated than normal tissues from which they arose. 
This so-called tumor hypoxia leads to resistance to radio-
therapy and anticancer chemotherapy, as well as predispos-
es to increased tumor metastases (Dhani et al., 2015). Ac-
cordingly, even though CAR-T cells are injected intra-
tumorally, tumor hypoxia is expected to affect CAR-T cell 
viability, which in turn will seriously reduce their therapeu-
tic efficacy. As part of a solution to this problem, we are 
developing new strategies, such as normalizing blood sup-
ply to the tumor prior to CAR-T cell injection.          
Development of immunotherapy against MUC1 raises 
two additional concerns. First, MUC1 is expressed at lower 
levels by several normal tissues. Nonetheless, this did not 
interfere in Ab-based therapeutic protocols targeting this 
antigen (Taylor-Papadimitriou et al., 2002; Beatson et al., 
2010; Kimura and Finn, 2013). Cells of a non-tumorigenic 
mammary cell line were not killed by CAR-T cells despite 
low-level expression of MUC1, according to another report. 
This may reflect the predominance of core two glycans on 
MUC1 in non-transformed cells (Dalziel et al., 2001; 
Mungul et al., 2004; Tarp et al., 2007; Blixt et al., 2011; 
Beatson et al., 2015) that inhibit HMFG2 binding (Wilkie et 
al., 2008). Together, these reports are reassuring when con-
sidering clinical risks posed by MUC1-targeting T-cells. A 
second concern of Ab-based immunotherapy comprises 
reduced efficacy due to binding of soluble antigen targets. 
The polyvalent nature of MUC1 raises the probability that 
Ab binding might produce large circulating immune com-
plexes, leading to immunopathology. However, binding of 
soluble MUC1 may favor the CAR-based approach, facili-
tating tumor-dependent T-cell expansion and persistence. 
Such a mechanism has been implicated in the in vivo effi-
cacy of CAR-grafted T-cells against B-cell tumors (Correa 
et al., 2003). We did not detect any apparent evidence of 
off-tumor toxicities accompanying the CAR-T cell dosage 
or intratumoral delivery used in our study, although blood 
was found in the patient’s stools after the patient consumed 
cleansing intestinal phosphate fluid. This suggested that the 
mutated SM3 scFv sequence (pSM3 scFv) provides a safer 
approach targeting cancer-associated MUC1. 
Some interesting pathological observations were made 
during this trial. First, the treated tumor biopsies were pre-
dominantly infiltrated with the CD8+ T-cells, with fewer 
CD4+ T-cells. Increasing evidence supports the existence of 
elevated Treg numbers in solid tumors and hematologic 
malignancies. Tregs, first identified by Sakaguchi (Saka- 
guchi et al., 2006), mediate peripheral tolerance to self and 
innocuous environmental antigens. Originally characterized 
as CD4+CD25+ lymphocytes, they also express the fork-
head/winged helix family transcription factor FoxP3. This is 
critical for both the development of Tregs and for their sup-
pressive capacities, and, to an extent, has enabled improved 
characterization of these cells (Oleinika et al., 2013). Since 
we used the aAPC (artificial antigen presenting cells) ap-
proach to prepare CAR-T cells, which resulted in 
CD8+-dominated CAR-T cells, the observation of few CD4+ 
T-cells and numerous CD8+ T-cells in the biopsies suggest-
ed that the infiltrating T-cells were CAR-T cells, which was 
further supported by immunostaining with Fc antibody (data 
not shown). Second, we found one major difference be-
tween biomarker expression by SM3-CAR-T- treated tumor 
and pSM3-CAR-T-treated tumor, namely, the former was 
TIA-1 positive while the latter was TIA-1 negative. TIA-1 
is an intracellular cytotoxic lymphocyte protein that is lo-
calized within cytoplasmic granules containing serine pro-
teases. It is a 15-kD-granule membrane-associated protein 
that can induce apoptotic cell death when introduced into 
permeabilized cells (Gross et al., 2001). Anti-TIA-1 MAbs 
detect a subpopulation of CD8+ T- and NK cells that have 
cytotoxic activity. Our observation could be partially ex-
plained by contributions of IL-12 to TIA-1 expression, since 
we induced IL-12 expression in SM3-CAR-T-treated tumor 
and IL-12 may recruit and activate NK cells and repel aner-
gic TILs. 
Overall, our findings of tumor necrosis induced by 
pSM3-CAR-T cells have significant implications for the 
role of CAR therapy in treating MUC1 positive carcinomas. 
The clinical activity, intervention treatment strategy, and an 
improved scFv-targeting of tumor-associated MUC1 sug-
gest that CAR-T cell therapy is a promising treatment mo-
dality for patients with solid malignancies. 
MATERIALS AND METHODS 
Patient background 
Patient#2 had an advanced left seminal vesicle cancer with 
extensive metastasis, and was enrolled into a clinical trial at 
the Suzhou Kowloon Hospital with the approval of The 
Ethics Committee of the Hospital. Written informed consent 
was obtained before the trial. This patient was first diag-
nosed with left seminal vesicle cancer in 2006.  
The last spiral CT scan of this patient was performed on 
February 25, 2015, and included chest, abdomen, and pel-
vis. When compared to an earlier CT scan from October 6, 
2014, the sizes of most metastatic lesions increased, some 
were unchanged, and some decreased. In the increased size 
lesions, the right upper lobe pleural implant increased from 
2.11.2 cm2 to 3.41.8 cm2. Dated pleural implant seen in 
the right paravertebral region increased from 1.9 to 2.4 cm. 
An implant seen in the right lower lobe increased from 1.2 
to 1.9 cm. Pleural nodularity involving the right major fis-
sure was also more prominent when compared to the earlier 
CT scan.  
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The metastatic lesions whose sizes decreased included 
left supraclavicular lymph node that was measured as 
2.51.9 cm2, compared with 2.92.2 cm2 in the earlier CT 
scan, and an implant on the right middle lobe minimally 
decreased in size from 1.5 to 1.4 cm. 
The majority of metastatic lesions were slightly bigger 
when compared with an earlier CT scan from December 23, 
2014. Left para-aortic metastatic lesion increased from 
2.11.9 cm2 to 2.32.2 cm2. A metastatic lesion adjacent to 
the body of the pancreas increased from 2.01.4 cm2 to 
2.61.7 cm2. Metastatic lesion in the interaortocaval region 
increased from 3.31.9 cm2 to 3.32.4 cm2. Metastatic le-
sion adjacent to the transverse colon increased from 1.91.2 
cm2 to 2.31.6 cm2. An additional interaortocaval lymph 
node lesion increased from 1.61.2 cm2 to 1.81.4 cm2. A 
metastatic lesion adjacent to the left renal hilum increased 
from 1.41.3 cm2 to 2.01.6 cm2. 
Some of the metastatic lesions were stable, e.g. one le-
sion adjacent to the right kidney measuring 1.81.3 cm2. 
The patient’s spleen was resected. Overall, no significant 
change was observed in the appearance of the dilated bile 
duct system. Some atrophy of the left kidney was detected, 
but no bilateral hydronephrosis was found. Surgical changes 
of colorectal anastomosis in the pelvic region were appar-
ent, with no overall significant change in soft tissue mass in 
the prostatic bed region. 
Clinical protocols 
Phase I clinical trial (NCT02587689) was designed to eval-
uate the manufacturing feasibility and safety of MUC1- 
CAR-T cells in patient with advanced seminal vesicle car-
cinoma. The patient received two intratumoral injections of 
SM3-CAR-T and pSM3-CAR-T cells into two separate tu-
mor lesions respectively, where one mass has a size of 38.1 
mm×23.7 mm located at right upper outer quadrant and 
another lesion is of 33.6 mm×22.8 mm located at inferior 
the xiphoid process region, demonstrated by axial CT (Fig-
ure S1 in Supporting Information). Both lesions received a 
dosage of 5×105 CAR-T cells, followed by serum cytokines 
monitoring. 21 d later after completing this treatment, gray-
scale ultrasound analysis and immunohistochemistry assays 
were performed to evaluate the clinical response. 
MUC1-CAR construction   
MUC1-CAR expression cassettes were designed as de-
scribed in the RESULTS. Briefly, SM3-CAR and pSM3- 
CAR expressing a single chain antibody of SM3, and a mu-
tated single chain antibody of SM3 (pSM3) were construct-
ed, with T cell activation signal, costimulatory signal, with 
IL-12 in SM3-CAR, or without IL-12 in pSM3-CAR. The 
lentiviral vector plasmid of pCDH-CMV-MCS-EF1-  
CopGFP was used as a gene transfer backbone vector. 
T cell culture   
20 mL of peripheral blood mononuclear cells (PBMC) were 
separated from patient blood using Ficoll (GE ) and sus-
pended at a concentration of 1×106 cells per mL in T cell 
medium. T cells were cultured on 24-well plates with the 
density of 1×106 cells per well and stimulated by pAPCCTL 
Kit (PersonGen Biomedicne (Suzhou) Co., Ltd, Suzhou). 
Briefly, on day 1 (one day after transduction by lentivirus-
es), the T cells were stimulated with -irradiated aAPCs at a 
1:2 T cell/aAPC ratio. aAPCs were added on day 7 during 
expansion. 100 IU mL1 of IL-2 (Novoprotein) alone or 
combined with 30 ng mL1 IL-21 (IL-21; eBioscience, Inc., 
USA) were added to the cultures every 48 h beginning on 
day 7. CAR-T cells were cultured for 12 d, and viable cells 
were counted on the basis of trypan blue exclusion. T cells 
that were not genetically modified were used as control T 
cells; these cells were propagated on g-irradiated aAPCs as 
well. 
Lentivirus production  
The packaging cells of 293T were maintained in 10% fetal 
bovine serum, 1% penicillin/streptomycin, and 1% non- 
essential amino acids in DMEM (Hyclone ) at 37C with 
5% CO2. The packaging plasmids were R, Rev, and 
VSV-G. Replication-defective lentiviral particles pseudo-
typed with VSV-G envelope were produced by transient 
transfection of 293T cells with 10 mg of the gene transfer 
constructs, 6.5 mg of R, 3.5 mg of VSV-G and 2.5 mg of 
Rev, using transfection reagents. The transfection medium 
was replaced after 12 h with fresh culture medium. Viral 
supernatants were harvested at 72 h after transfection and 
filtered through 0.22 mm filters. Supernatants were either 
used immediately for transductions or were aliquoted and 
stored at 80°C until use. Titers of viral supernatants were 
determined by transducing 293T cells with serial dilutions 
of viral supernatants, followed by flow cytometry analysis 
of Fc-positive cells, 48 h after transduction. 
Lentiviral transduction     
To determine transduction efficiency, T cells were used to 
transduce with lentivirus harvested from 293T cell transfec-
tion. T cells (5×105) were counted, placed in wells of 
24-well plates, and inoculated with lentiviral supernatants 
above (MOI=30). The transduced cells were incubated at 
37°C for 4–6 h, and then the supernatants were removed 
and replaced with 2 mL volume of fresh 10% RPMI-1640 
medium (Hyclone, GE Healthcare Bio-Sciences, USA). At 
72 h post-transduction, T cells were performed Fc im-
munostaining and observed by fluorescence microscope 
qualitatively and analyzed by FACSCalibur (BD Biosci-
ences, USA). 
CAR detection on transduced T cells 
Transduced T cells were analyzed using FACSCalibur (BD) 
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to determine the Fc-positive cell ratio. Cells were washed 
and suspended in phosphate-buffered saline (PBS), and 
subjected to flow cytometry assay. 
Cytotoxicity assay  
T47D tumor cell line (purchased from ATCC) that is highly 
expressing endogenous MUC1 were labeled with CFSE 
(carboxyfluorescein succinimidyl ester, BD). CFSE-loaded 
T47D cells were mixed with SM3-CAR-T cells and 
pSM3-CAR-T cells respectively at a ratio of 5:1 and 30:1, 
and incubated for 24 h. Untransduced T cells were served as 
negative controls. After 24 h of co-culture, cells were 
stained with 7-AAD (7-aminoactinomycin D, BD), and the 
percentage of dead tumor cells (CFSE positive and 7-AAD 
positive) was determined. 
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